PerkinElmer Announces Financial Results for the Fourth Quarter and Full Year 2018

  • Fourth Quarter 2018 GAAP revenue growth of 18% to $756.3 million; Core organic revenue growth of 7%
  • Fourth Quarter 2018 GAAP earnings per share from continuing operations of $0.64; Adjusted earnings per share of $1.18
  • Receives CE-IVD Mark for Vanadis NIPT
  • Initiates FY19 GAAP earnings per share guidance range of $2.93 to $2.98 from continuing operations; Adjusted EPS guidance of $4.00 to $4.05

WALTHAM, Mass.--()--PerkinElmer, Inc. (NYSE: PKI), a global leader committed to innovating for a healthier world, today reported financial results for the fourth quarter and full year ended December 30, 2018.

Fourth Quarter 2018
The Company reported GAAP earnings per share from continuing operations of $0.64, as compared to GAAP losses per share from continuing operations of $0.35, including the impact of the Tax Cuts and Jobs Act of 2017, in the fourth quarter of 2017. GAAP revenue for the quarter was $756.3 million, as compared to $641.6 million in the fourth quarter of 2017. GAAP operating income from continuing operations for the quarter was $115.7 million, as compared to $93.6 million in the fourth quarter of 2017. GAAP operating profit margin was 15.3% as a percentage of revenue.

Adjusted earnings per share from continuing operations for the quarter was $1.18, as compared to $0.97 in the fourth quarter of 2017. Adjusted revenue for the quarter was $756.5 million, as compared to $641.8 million in the fourth quarter of 2017. Adjusted operating income from continuing operations for the quarter was $164.3 million, as compared to $135.3 million for the same period a year ago. Adjusted operating profit margin was 21.7% as a percentage of adjusted revenue.

Full Year 2018
The Company reported GAAP earnings per share from continuing operations of $2.13, as compared to GAAP earnings per share from continuing operations of $1.42, including the impact of the Tax Cuts and Jobs Act of 2017, in 2017. GAAP revenue for the year was $2.78 billion, as compared to $2.26 billion in 2017. GAAP operating income from continuing operations for the year was $323.9 million, as compared to $295.6 million in 2017. GAAP operating profit margin was 11.7% as a percentage of revenue.

Adjusted earnings per share from continuing operations for the year was $3.61, as compared to $2.90 in 2017. Adjusted revenue for the year was $2.78 billion, as compared to $2.26 billion in 2017. Adjusted operating income from continuing operations for the year was $527.1 million, as compared to $420.6 million in 2017. Adjusted operating profit margin was 19.0% as a percentage of adjusted revenue.

Adjustments for the Company's non-GAAP financial measures have been noted in the attached reconciliations.

“We were very pleased with our fourth quarter and full year performance and believe 2018 will mark an inflection point in our revenue growth, profitability and, just as importantly, our ability to make an increasingly positive impact on the quality of life across the globe,” said Robert Friel, chairman and chief executive officer of PerkinElmer.

Financial Overview by Reporting Segment for the Fourth Quarter and Full Year 2018

Discovery & Analytical Solutions

  • Fourth quarter 2018 revenue was $459.9 million, as compared to $448.2 million for the comparable prior period. Reported revenue increased 3% and organic revenue increased 5%. Full year 2018 revenue was $1.69 billion, as compared to $1.58 billion in 2017. Full year reported and organic revenue increased 7%.
  • Fourth quarter 2018 operating income from continuing operations was $81.2 million, as compared to $76.7 million for the comparable prior period. Full year 2018 operating income of $230.5 million, as compared to $205.3 million in 2017.
  • Fourth quarter 2018 adjusted operating income was $92.7 million, as compared to $93.3 million for the comparable prior period. Full year 2018 adjusted operating income was $295.0 million, as compared to $269.5 million in 2017.

Diagnostics

  • Fourth quarter 2018 revenue was $296.5 million, as compared to $193.4 million for the comparable prior period. Reported revenue increased 53% and organic revenue increased 14%. Full year 2018 revenue was $1.08 billion, as compared to $678.5 million in 2017. Full year reported revenue increased 60% and organic revenue increased 10%.
  • Fourth quarter 2018 operating income from continuing operations was $48.6 million, as compared to $33.8 million for the comparable prior period. Full year 2018 operating income was $153.2 million, as compared to $146.9 million in 2017.
  • Fourth quarter 2018 adjusted operating income was $85.8 million, as compared to $58.9 million for the comparable prior period. Full year 2018 adjusted operating income was $291.9 million, as compared to $207.7 million in 2017.

Initiates Financial Guidance – Full Year 2019

For the full year 2019, the Company forecasts GAAP earnings per share from continuing operations in a range of $2.93 to $2.98 and, on a non-GAAP basis, which is expected to include the adjustments noted in the attached reconciliation, adjusted earnings per share of $4.00 to $4.05.

Conference Call Information

The Company will discuss its fourth quarter and full year 2018 results and its outlook for business trends in a conference call on January 31, 2019 at 5:00 p.m. Eastern Time. To access the call, please dial (720) 405-2250 prior to the scheduled conference call time and provide the access code 6958164.

A live audio webcast of the call will be available on the Investor section of the Company’s Web site, www.perkinelmer.com. Please go to the site at least 15 minutes prior to the call in order to register, download, and install any necessary software. An archived version of the webcast will be posted on the Company’s Web site for a two week period beginning approximately two hours after the call.

Use of Non-GAAP Financial Measures

In addition to financial measures prepared in accordance with generally accepted accounting principles (GAAP), this earnings announcement also contains non-GAAP financial measures. The reasons that we use these measures, a reconciliation of these measures to the most directly comparable GAAP measures, and other information relating to these measures are included below following our GAAP financial statements.

Factors Affecting Future Performance

This press release contains "forward-looking" statements within the meaning of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements relating to estimates and projections of future earnings per share, cash flow and revenue growth and other financial results, developments relating to our customers and end-markets, and plans concerning business development opportunities, acquisitions and divestitures. Words such as "believes," "intends," "anticipates," "plans," "expects," "projects," "forecasts," "will" and similar expressions, and references to guidance, are intended to identify forward-looking statements. Such statements are based on management's current assumptions and expectations and no assurances can be given that our assumptions or expectations will prove to be correct. A number of important risk factors could cause actual results to differ materially from the results described, implied or projected in any forward-looking statements. These factors include, without limitation: (1) markets into which we sell our products declining or not growing as anticipated; (2) fluctuations in the global economic and political environments; (3) our failure to introduce new products in a timely manner; (4) our ability to execute acquisitions and license technologies, or to successfully integrate acquired businesses such as EUROIMMUN and licensed technologies into our existing business or to make them profitable, or successfully divest businesses; (5) our failure to adequately protect our intellectual property; (6) the loss of any of our licenses or licensed rights; (7) our ability to compete effectively; (8) fluctuation in our quarterly operating results and our ability to adjust our operations to address unexpected changes; (9) significant disruption in third-party package delivery and import/export services or significant increases in prices for those services; (10) disruptions in the supply of raw materials and supplies; (11) the manufacture and sale of products exposing us to product liability claims; (12) our failure to maintain compliance with applicable government regulations; (13) regulatory changes; (14) our failure to comply with healthcare industry regulations; (15) economic, political and other risks associated with foreign operations; (16) our ability to retain key personnel; (17) significant disruption in our information technology systems; (18) our ability to obtain future financing; (19) restrictions in our credit agreements; (20) the United Kingdom’s intention to withdraw from the European Union; (21) our ability to realize the full value of our intangible assets; (22) significant fluctuations in our stock price; (23) reduction or elimination of dividends on our common stock; and (24) other factors which we describe under the caption "Risk Factors" in our most recent quarterly report on Form 10-Q and in our other filings with the Securities and Exchange Commission. We disclaim any intention or obligation to update any forward-looking statements as a result of developments occurring after the date of this press release.

About PerkinElmer

PerkinElmer, Inc. is a global leader focused on innovating for a healthier world. The Company reported revenue of approximately $2.8 billion in 2018, has about 12,500 employees serving customers in more than 150 countries, and is a component of the S&P 500 Index. Additional information is available through 1-877-PKI-NYSE, or at www.perkinelmer.com.

           
PerkinElmer, Inc. and Subsidiaries
CONDENSED CONSOLIDATED INCOME STATEMENTS
       

Three Months Ended

Twelve Months Ended

 
(In thousands, except per share data)

December 30, 2018

December 31, 2017

December 30, 2018

December 31, 2017

 
Revenue $ 756,349 $ 641,630 $ 2,777,996 $ 2,256,982
 
Cost of revenue 380,099 334,201 1,437,057 1,183,228
Selling, general and administrative expenses 210,539 176,376 811,913 626,018
Research and development expenses 51,970 37,733 193,998 139,464
Restructuring and contract termination charges, net   (1,942 )   (263 )   11,144     12,657  
 
Operating income from continuing operations 115,683 93,583 323,884 295,615
 
Interest income (387 ) (1,059 ) (1,141 ) (2,571 )
Interest expense 16,231 11,430 66,976 43,940
Loss or (gain) on disposition of businesses and assets, net 187 8 (12,844 ) 309
Other expense (income), net   20,223     2,315     13,210     (42,781 )
 
Income from continuing operations, before income taxes 79,429 80,889 257,683 296,718
 
Provision for income taxes   8,107     119,333     20,208     139,828  
 
Income (loss) from continuing operations 71,322 (38,444 ) 237,475 156,890
 
Income from discontinued operations, before income taxes - - - 650
(Loss) gain on disposition of discontinued operations, before income taxes - (556 ) (859 ) 179,615
Provision for (benefit from) income taxes on discontinued operations and dispositions   30     2,117     (1,311 )   44,522  
 
Loss (gain) from discontinued operations and dispositions   (30 )   (2,673 )   452     135,743  
 
Net income (loss) $ 71,292   $ (41,117 ) $ 237,927   $ 292,633  
 
 
Diluted earnings per share:
Income from continuing operations $ 0.64 $ (0.35 ) $ 2.13 $ 1.42
 
Gain (loss) from discontinued operations and dispositions   (0.00 )   (0.02 )   0.00     1.22  
 
Net income (loss) $ 0.64   $ (0.37 ) $ 2.13   $ 2.64  
 
 
Weighted average shares of common stock outstanding 111,609 110,064 111,534 110,859

diluted

basic

diluted

diluted

 
ABOVE PREPARED IN ACCORDANCE WITH GAAP
 
Additional Supplemental Information (1):
(per share, continuing operations)
 
GAAP EPS from continuing operations $ 0.64 $ (0.35 ) $ 2.13 $ 1.42
Amortization of intangible assets 0.32 0.19 1.22 0.66
Purchase accounting adjustments 0.05 0.03 0.31 0.08
Significant litigation matter 0.00 0.02 0.05 0.02
Acquisition and divestiture-related costs 0.09 0.20 0.14 (0.08 )
Disposition of businesses and assets, net 0.00 0.00 (0.12 ) 0.00
Mark to market on postretirement benefits 0.19 (0.02 ) 0.19 (0.02 )
Restructuring and contract termination charges, net (0.02 ) (0.00 ) 0.10 0.11
Tax on above items (0.12 ) (0.07 ) (0.40 ) (0.27 )
Impact of tax act   0.03     0.97     (0.02 )   0.96  
Adjusted EPS $ 1.18   $ 0.97   $ 3.61   $ 2.90  
 
(1) amounts may not sum due to rounding                            
 

 
PerkinElmer, Inc. and Subsidiaries
REVENUE AND OPERATING INCOME (LOSS)
                     

Three Months Ended

Twelve Months Ended

(In thousands, except percentages)

December 30, 2018

December 31, 2017

December 30, 2018

December 31, 2017

 
 
DAS Reported revenue

 

$

459,892

 

$

448,189

 

$

1,693,211

 

$

1,578,459

 
Reported operating income from continued operations 81,238 76,655 230,481 205,259
OP% 17.7 % 17.1 % 13.6 % 13.0 %
Amortization of intangible assets 11,553 13,224 46,120 50,677
Purchase accounting adjustments 308 16 409 64
Acquisition and divestiture-related costs 921 - 2,680 348
Significant litigation matter 297 2,700 5,347 2,700
Restructuring and contract termination charges, net   (1,606 )   730     9,960     10,446  
Adjusted operating income   92,711     93,325     294,997     269,494  
Adjusted OP% 20.2 % 20.8 % 17.4 % 17.1 %
 
Diagnostics Reported revenue 296,457 193,441 1,084,785 678,523
Purchase accounting adjustments   190     189     752     745  
Adjusted revenue   296,647     193,630     1,085,537     679,268  
 
Reported operating income from continued operations 48,611 33,838 153,196 146,862
OP% 16.4 % 17.5 % 14.1 % 21.6 %
Amortization of intangible assets 23,703 8,176 89,815 22,983
Purchase accounting adjustments 4,860 2,753 34,377 9,153
Acquisition and divestiture-related costs 8,955 15,080 13,131 26,448
Significant litigation matter (0 ) - 193 -
Restructuring and contract termination charges, net   (336 )   (993 )   1,184     2,211  
Adjusted operating income   85,792     58,854     291,895     207,657  
Adjusted OP% 28.9 % 30.4 % 26.9 % 30.6 %
 
Corporate Reported operating loss (14,166 ) (16,910 ) (59,793 ) (56,506 )
 
Continuing Operations Reported revenue

 

$

756,349

 

$

641,630

 

$

2,777,996

 

$

2,256,982

Purchase accounting adjustments   190     189     752     745  
Adjusted revenue   756,539     641,819     2,778,748     2,257,727  
 
Reported operating income from continued operations 115,683 93,583 323,884 295,615
OP% 15.3 % 14.6 % 11.7 % 13.1 %
Amortization of intangible assets 35,256 21,400 135,935 73,660
Asset impairment - - - -
Purchase accounting adjustments 5,168 2,769 34,786 9,217
Acquisition and divestiture-related costs 9,876 15,080 15,811 26,796
Significant litigation matter 297 2,700 5,540 2,700
Restructuring and contract termination charges, net   (1,942 )   (263 )   11,144     12,657  
Adjusted operating income

 

$

164,337

 

 

$

135,269

 

 

$

527,099

 

 

$

420,645

 
Adjusted OP% 21.7 % 21.1 % 19.0 % 18.6 %
 
REPORTED REVENUE AND REPORTED OPERATING INCOME (LOSS) PREPARED IN ACCORDANCE WITH GAAP
 

 
PerkinElmer, Inc. and Subsidiaries
CONDENSED CONSOLIDATED BALANCE SHEETS
       
(In thousands)

December 30, 2018

December 31, 2017

 
Current assets:
Cash and cash equivalents $ 163,111 $ 202,134
Accounts receivable, net 632,669 552,304
Inventories, net 338,347 351,675
Other current assets   100,507     93,842  
Total current assets   1,234,634     1,199,955  
 
Property, plant and equipment:
At cost 739,647 630,919
Accumulated depreciation   (421,057 )   (332,853 )
Property, plant and equipment, net 318,590 298,066
Intangible assets, net 1,199,667 1,346,940
Goodwill 2,952,558 3,002,198
Other assets, net   270,023     244,304  
Total assets $ 5,975,472   $ 6,091,463  
 
Current liabilities:
Current portion of long-term debt $ 15,838 $ 217,306
Accounts payable 220,949 222,093
Short-term accrued restructuring and contract termination charges 4,834 8,759
Accrued expenses and other current liabilities 528,827 500,642
Current liabilities of discontinued operations   2,165     2,102  
Total current liabilities   772,613     950,902  
 
Long-term debt 1,875,642 1,788,803
Long-term liabilities   742,262     848,570  
Total liabilities   3,390,517     3,588,275  
 
Total stockholders' equity   2,584,955     2,503,188  
Total liabilities and stockholders' equity $ 5,975,472   $ 6,091,463  
 
PREPARED IN ACCORDANCE WITH GAAP
 

 
PerkinElmer, Inc. and Subsidiaries
CONSOLIDATED STATEMENTS OF CASH FLOWS
               

Three Months Ended

Twelve Months Ended

December 30, 2018

December 31, 2017

December 30, 2018

December 31, 2017

(In thousands) (In thousands)
 
Operating activities:
Net income (loss) $ 71,292 ($41,117 ) $ 237,927 $ 292,633
(Gain) loss from discontinued operations and dispositions, net of income taxes   30     2,673     (452 )   (135,743 )
Income (loss) from continuing operations   71,322     (38,444 )   237,475     156,890  
Adjustments to reconcile income (loss) from continuing operations
to net cash provided by continuing operations:
Stock-based compensation 5,492 9,242 28,767 25,421
Restructuring and contract termination charges, net (1,942 ) (263 ) 11,144 12,657
Depreciation and amortization 47,202 29,493 180,588 105,000
Pension and other postretirement (benefits) expenses 11,915 (10,439 ) 11,915 (10,439 )
Change in fair value of contingent consideration 3,835 602 14,639 2,162
Amortization of deferred debt financing costs and accretion of discounts 887 656 3,341 2,592
Loss (gain) on disposition of businesses and assets, net 187 8 (12,844 ) 309
Gain on sale of investments, net - - (557 ) -
Amortization of acquired inventory revaluation 1,112 1,948 19,272 6,188
Deferred taxes (33,634 ) 25,277 (33,634 ) 28,854
Contingencies and non-cash tax matters (671 ) 1,313 (671 ) 182
Changes in assets and liabilities which provided (used) cash, excluding
effects from companies acquired:
Accounts receivable, net (81,842 ) (47,604 ) (94,512 ) (36,633 )
Inventories 11,129 7,285 (30,183 ) (17,923 )
Accounts payable 45,487 46,791 8,900 34,331
Accrued expenses and other   78,940     102,233     (32,402 )   (17,436 )
Net cash provided by operating activities of continuing operations 159,419 128,098 311,238 292,155
Net cash used in operating activities of discontinued operations   -     -     (200 )   (3,702 )
Net cash provided by operating activities   159,419     128,098     311,038     288,453  
 
Investing activities:
Capital expenditures (32,810 ) (16,728 ) (93,253 ) (39,089 )
Settlement of cash flow hedges - (23,879 ) - 36,541
Purchases of investments (1,519 ) (10,783 ) (7,019 ) (10,783 )
Proceeds from surrender of life insurance policies - - 72 45
Proceeds from disposition of businesses and assets - 1,100 38,027 1,100
Payment of acquisitions, net of cash and cash equivalents acquired   (53,629 )   (1,403,606 )   (97,686 )   (1,527,183 )
Net cash used in by investing activities of continuing operations (87,958 ) (1,453,896 ) (159,859 ) (1,539,369 )
Net cash provided by investing activities of discontinued operations   -     -     -     272,779  
Net cash used in investing activities   (87,958 )   (1,453,896 )   (159,859 )   (1,266,590 )
 
Financing Activities:
Payments on borrowings (245,000 ) (89,000 ) (1,264,000 ) (235,965 )
Proceeds from borrowings 252,000 914,000 857,000 1,060,952
Proceeds from sale of senior debt - - 369,340 -
Payments of debt issuance costs - - (2,634 ) -
Settlement of cash flow hedges (3,847 ) (2,285 ) (34,132 ) (13,824 )
Net payments on other credit facilities (5,512 ) (1,959 ) (28,383 ) (2,831 )
Payments for acquisition-related contingent consideration - - (12,800 ) (8,940 )
Proceeds from issuance of common stock under stock plans 5,348 4,000 24,833 18,004
Purchases of common stock (52,471 ) (354 ) (57,445 ) (3,834 )
Dividends paid   (7,787 )   (7,716 )   (31,009 )   (30,793 )
Net cash (used in) provided by financing activities of continuing operations (57,269 ) 816,686 (179,230 ) 782,769
Net cash used in financing activities of discontinued operations   -     -     -     (533 )
Net cash (used in) provided by financing activities (57,269 ) 816,686 (179,230 ) 782,236
 
Effect of exchange rate changes on cash, cash equivalents, and restricted cash   (594 )   1,759     (8,004 )   21,703  
 
Net increase (decrease) in cash, cash equivalents, and restricted cash 13,598 (507,353 ) (36,055 ) (174,198 )
Cash, cash equivalents, and restricted cash at beginning of period   152,717     709,723     202,370     376,568  
Cash, cash equivalents, and restricted cash at end of period $ 166,315   $ 202,370   $ 166,315   $ 202,370  
 
 
Supplemental disclosure of cash flow information:
 
Reconciliation of cash, cash equivalents and restricted cash reported within the consolidated balance sheets that sum to the total shown in the consolidated statements of cash flows:
Cash and cash equivalents 163,111 202,134 163,111 202,134
Restricted cash included in other current assets   3,204     236     3,204     236  
Total cash, cash equivalents and restricted cash $ 166,315   $ 202,370   $ 166,315   $ 202,370  
 
PREPARED IN ACCORDANCE WITH GAAP
 

 
PerkinElmer, Inc. and Subsidiaries
RECONCILIATION OF GAAP TO NON-GAAP FINANCIAL MEASURES (1)
                           
(In millions, except per share data and percentages) PKI
Three Months Ended

December 30, 2018

       

December 31, 2017

   
 
Adjusted revenue:
Revenue $ 756.3 $ 641.6
Purchase accounting adjustments   0.2               0.2        
Adjusted revenue $ 756.5             $ 641.8        
 
Adjusted gross margin:
Gross margin $ 376.3 49.7 % $ 307.4 47.9 %
Amortization of intangible assets 11.4 1.5 % 7.9 1.2 %
Purchase accounting adjustments   1.3       0.2 %       2.2       0.3 %
Adjusted gross margin $ 389.0       51.4 %     $ 317.5       49.5 %
 
Adjusted SG&A:
SG&A $ 210.5 27.8 % $ 176.4 27.5 %
Amortization of intangible assets (19.8 ) -2.6 % (13.4 ) -2.1 %
Purchase accounting adjustments (3.8 ) -0.5 % (0.6 ) -0.1 %
Acquisition and divestiture-related expenses (9.9 ) -1.3 % (15.1 ) -2.4 %
Significant litigation matter   (0.3 )     0.0 %       (2.7 )     -0.4 %
Adjusted SG&A $ 176.7       23.4 %     $ 144.6       22.5 %
 
Adjusted R&D:
R&D $ 52.0 6.9 % $ 37.7 5.9 %
Amortization of intangible assets   (4.1 )     -0.5 %       (0.1 )     0.0 %
Adjusted R&D $ 47.9       6.3 %     $ 37.7       5.9 %
 
Adjusted operating income:
Operating income $ 115.7 15.3 % $ 93.6 14.6 %
Amortization of intangible assets 35.3 4.7 % 21.4 3.3 %
Purchase accounting adjustments 5.2 0.7 % 2.8 0.4 %
Acquisition and divestiture-related expenses 9.9 1.3 % 15.1 2.4 %
Significant litigation matter 0.3 0.0 % 2.7 0.4 %
Restructuring and contract termination charges, net   (1.9 )     -0.3 %       (0.3 )     0.0 %
Adjusted operating income $ 164.3       21.7 %     $ 135.3       21.1 %
                   
PKI
Three Months Ended

December 30, 2018

December 31, 2017

 
Adjusted EPS:
GAAP EPS $ 0.64 $ (0.37 )
Discontinued operations, net of income taxes   (0.00 )             (0.02 )      
GAAP EPS from continuing operations 0.64 (0.35 )
Amortization of intangible assets 0.32 0.19
Purchase accounting adjustments 0.05 0.03
Significant litigation matter 0.00 0.02
Acquisition and divestiture-related expenses 0.09 0.20
Gain on disposition of businesses and assets, net 0.00 0.00
Mark to market on postretirement benefits 0.19 (0.02 )
Restructuring and contract termination charges, net (0.02 ) (0.00 )
Tax on above items (0.12 ) (0.07 )
Impact of tax act   0.03               0.97        
Adjusted EPS $ 1.18             $ 0.97        
                   
DAS
Three Months Ended

December 30, 2018

December 31, 2017

 
Revenue $ 459.9 $ 448.2
 
Adjusted operating income:
Operating income $ 81.2 17.7 % $ 76.7 17.1 %
Amortization of intangible assets 11.6 2.5 % 13.2 3.0 %
Purchase accounting adjustments 0.3 0.1 % 0.0 0.0 %
Acquisition and divestiture-related expenses 0.9 0.2 % - 0.0 %
Significant litigation matter 0.3 0.1 % 2.7 0.6 %
Restructuring and contract termination charges, net   (1.6 )     -0.3 %       0.7       0.2 %
Adjusted operating income $ 92.7       20.2 %     $ 93.3       20.8 %
                   
Diagnostics
Three Months Ended

December 30, 2018

December 31, 2017

 
Adjusted revenue:
Revenue $ 296.5 $ 193.4
Purchase accounting adjustments   0.2               0.2        
Adjusted revenue $ 296.6             $ 193.6        
 
Adjusted operating income:
Operating income $ 48.6 16.4 % $ 33.8 17.5 %
Amortization of intangible assets 23.7 8.0 % 8.2 4.2 %
Purchase accounting adjustments 4.9 1.6 % 2.8 1.4 %
Acquisition and divestiture-related expenses 9.0 3.0 % 15.1 7.8 %
Significant litigation matter (0.0 ) 0.0 % - 0.0 %
Restructuring and contract termination charges, net   (0.3 )     -0.1 %       (1.0 )     -0.5 %
Adjusted operating income $ 85.8       28.9 %     $ 58.9       30.4 %
 
(1) amounts may not sum due to rounding
 

               
PerkinElmer, Inc. and Subsidiaries
RECONCILIATION OF GAAP TO NON-GAAP FINANCIAL MEASURES (1)
                   
(In millions, except per share data and percentages) PKI
Twelve Months Ended

December 30, 2018

December 31, 2017

 
Adjusted revenue:
Revenue $ 2,778.0 $ 2,257.0
Purchase accounting adjustments   0.8               0.7        
Adjusted revenue $ 2,778.7             $ 2,257.7        
 
Adjusted gross margin:
Gross margin $ 1,340.9 48.3 % $ 1,073.8 47.6 %
Amortization of intangible assets 46.2 1.7 % 29.3 1.3 %
Purchase accounting adjustments   20.1       0.7 %       7.0       0.3 %
Adjusted gross margin $ 1,407.3       50.6 %     $ 1,110.0       49.2 %
 
Adjusted SG&A:
SG&A $ 811.9 29.2 % $ 626.0 27.7 %
Amortization of intangible assets (81.8 ) -2.9 % (44.1 ) -2.0 %
Purchase accounting adjustments (14.7 ) -0.5 % (2.2 ) -0.1 %
Acquisition and divestiture-related expenses (15.8 ) -0.6 % (26.8 ) -1.2 %
Significant litigation matter   (5.5 )     -0.2 %       (2.7 )     -0.1 %
Adjusted SG&A $ 694.1       25.0 %     $ 550.2       24.4 %
 
Adjusted R&D:
R&D $ 194.0 7.0 % $ 139.5 6.2 %
Amortization of intangible assets   (7.9 )     -0.3 %       (0.3 )     0.0 %
Adjusted R&D $ 186.1       6.7 %     $ 139.1       6.2 %
 
Adjusted operating income:
Operating income $ 323.9 11.7 % $ 295.6 13.1 %
Amortization of intangible assets 135.9 4.9 % 73.7 3.3 %
Purchase accounting adjustments 34.8 1.3 % 9.2 0.4 %
Acquisition and divestiture-related expenses 15.8 0.6 % 26.8 1.2 %
Significant litigation matter 5.5 0.2 % 2.7 0.1 %
Restructuring and contract termination charges, net   11.1       0.4 %       12.7       0.6 %
Adjusted operating income $ 527.1       19.0 %     $ 420.6       18.6 %
                   

PKI

Twelve Months Ended

December 30, 2018

December 31, 2017

 
Adjusted EPS:
GAAP EPS $ 2.13 $ 2.64
Discontinued operations   0.00               1.22        
GAAP EPS from continuing operations 2.13 1.42
Amortization of intangible assets 1.22 0.66
Purchase accounting adjustments 0.31 0.08
Significant litigation matter 0.05 0.02
Acquisition and divestiture-related expenses 0.14 (0.08 )
Gain on disposition of businesses and assets, net (0.12 ) 0.00
Mark to market on postretirement benefits 0.19 (0.02 )
Restructuring and contract termination charges, net 0.10 0.11
Tax on above items (0.40 ) (0.27 )
Impact of tax act   (0.02 )             0.96        
Adjusted EPS $ 3.61             $ 2.90        
                   
PKI
Twelve Months Ended

December 29, 2019

Adjusted EPS: Projected
GAAP EPS from continuing operations $2.93 - $2.98
Amortization of intangible assets 1.34
Purchase accounting adjustments 0.05
Acquisition and divestiture-related expenses 0.01
Tax on above items             (0.33 )      
Adjusted EPS             $4.00 - $4.05        
                   
DAS
Twelve Months Ended

December 30, 2018

December 31, 2017

 
Revenue $ 1,693.2 $ 1,578.5
 
Adjusted operating income:
Operating income $ 230.5 13.6 % $ 205.3 13.0 %
Amortization of intangible assets 46.1 2.7 % 50.7 3.2 %
Purchase accounting adjustments 0.4 0.0 % 0.1 0.0 %
Acquisition and divestiture-related expenses 2.7 0.2 % 0.3 0.0 %
Significant litigation matter 5.3 0.3 % 2.7 0.2 %
Restructuring and contract termination charges, net   10.0       0.6 %       10.4       0.7 %
Adjusted operating income $ 295.0       17.4 %     $ 269.5       17.1 %
                   
Diagnostics
Twelve Months Ended

December 30, 2018

December 31, 2017

 
Adjusted revenue:
Revenue $ 1,084.8 $ 678.5
Purchase accounting adjustments   0.8               0.7        
Adjusted revenue $ 1,085.5             $ 679.3        
 
Adjusted operating income:
Operating income $ 153.2 14.1 % $ 146.9 21.6 %
Amortization of intangible assets 89.8 8.3 % 23.0 3.4 %
Purchase accounting adjustments 34.4 3.2 % 9.2 1.3 %
Acquisition and divestiture-related expenses 13.1 1.2 % 26.4 3.9 %
Significant litigation matter 0.2 0.0 % - 0.0 %
Restructuring and contract termination charges, net   1.2       0.1 %       2.2       0.3 %
Adjusted operating income $ 291.9       26.9 %     $ 207.7       30.6 %
 
(1) amounts may not sum due to rounding
 

 
PerkinElmer, Inc. and Subsidiaries
RECONCILIATION OF GAAP TO NON-GAAP FINANCIAL MEASURES (1)
       
 

PKI

Three Months Ended

December 30, 2018

Organic revenue growth:
Reported revenue growth 18%
Less: effect of foreign exchange rates -2%
Less: effect of acquisitions including purchase accounting adjustments and impact of divested businesses 12%
Organic revenue growth 8%
Less: effect of EUROIMMUN 1%
Core organic revenue growth 7%
 
 

DAS

Three Months Ended

December 30, 2018

Organic revenue growth:
Reported revenue growth 3%
Less: effect of foreign exchange rates -2%
Less: effect of acquisitions including purchase accounting adjustments and impact of divested businesses 0%
Organic revenue growth 5%
 
 

Diagnostics

Three Months Ended

December 30, 2018

Organic revenue growth:
Reported revenue growth 53%
Less: effect of foreign exchange rates -3%
Less: effect of acquisitions including purchase accounting adjustments and impact of divested businesses 43%
Organic revenue growth 14%
 
(1) amounts may not sum due to rounding
 

 
PerkinElmer, Inc. and Subsidiaries
RECONCILIATION OF GAAP TO NON-GAAP FINANCIAL MEASURES (1)
       
 

PKI

Twelve Months Ended

December 30, 2018

Organic revenue growth:
Reported revenue growth 23%
Less: effect of foreign exchange rates 1%
Less: effect of acquisitions including purchase accounting adjustments and impact of divested businesses 14%
Organic revenue growth 8%
Less: effect of EUROIMMUN 1%
Core organic revenue growth 7%
 
 

DAS

Twelve Months Ended

December 30, 2018

Organic revenue growth:
Reported revenue growth 7%
Less: effect of foreign exchange rates 1%
Less: effect of acquisitions including purchase accounting adjustments and impact of divested businesses 0%
Organic revenue growth 7%
 
 

Diagnostics

Twelve Months Ended

December 30, 2018

Organic revenue growth:
Reported revenue growth 60%
Less: effect of foreign exchange rates 0%
Less: effect of acquisitions including purchase accounting adjustments and impact of divested businesses 49%
Organic revenue growth 10%
 
(1) amounts may not sum due to rounding
 

Explanation of Non-GAAP Financial Measures

We report our financial results in accordance with GAAP. However, management believes that, in order to more fully understand our short-term and long-term financial and operational trends, investors may wish to consider the impact of certain non-cash, non-recurring or other items, which result from facts and circumstances that vary in frequency and impact on continuing operations. Accordingly, we present non-GAAP financial measures as a supplement to the financial measures we present in accordance with GAAP. These non-GAAP financial measures provide management with additional means to understand and evaluate the operating results and trends in our ongoing business by adjusting for certain non-cash expenses and other items that management believes might otherwise make comparisons of our ongoing business with prior periods more difficult, obscure trends in ongoing operations, or reduce management's ability to make useful forecasts. Management believes these non-GAAP financial measures provide additional means of evaluating period-over-period operating performance. In addition, management understands that some investors and financial analysts find this information helpful in analyzing our financial and operational performance and comparing this performance to our peers and competitors.

We use the term “adjusted revenue” to refer to GAAP revenue, including purchase accounting adjustments for revenue from contracts acquired in acquisitions that will not be fully recognized due to accounting rules. We use the related term “adjusted revenue growth” to refer to the measure of comparing current period adjusted revenue with the corresponding period of the prior year.

We use the term “organic revenue” to refer to GAAP revenue, excluding the effect of foreign currency changes and including acquisitions growth from the comparable prior period, and including purchase accounting adjustments for revenue from contracts acquired in acquisitions that will not be fully recognized due to accounting rules. We also exclude the impact of sales from divested businesses by deducting the effects of divested business revenue from the current and prior periods. We use the related term “organic revenue growth” to refer to the measure of comparing current period organic revenue with the corresponding period of the prior year.

We use the term “core organic revenue” to refer to GAAP revenue excluding EUROIMMUN, excluding the effect of foreign currency changes and including acquisitions growth from the comparable prior period, and including purchase accounting adjustments for revenue from contracts acquired in acquisitions that will not be fully recognized due to accounting rules. We also exclude the impact of sales from divested businesses by deducting the effects of divested business revenue from the current and prior periods. We use the related term “core organic revenue growth” to refer to the measure of comparing current period core organic revenue with the corresponding period of the prior year.

We use the term “adjusted gross margin” to refer to GAAP gross margin, excluding amortization of intangible assets and inventory fair value adjustments related to business acquisitions, and including purchase accounting adjustments for revenue from contracts acquired in acquisitions that will not be fully recognized due to business combination accounting rules. We use the related term “adjusted gross margin percentage” to refer to adjusted gross margin as a percentage of adjusted revenue.

We use the term “adjusted SG&A expense” to refer to GAAP SG&A expense, excluding amortization of intangible assets, purchase accounting adjustments, acquisition and divestiture-related expenses, significant litigation matters and significant environmental charges. We use the related term “adjusted SG&A percentage” to refer to adjusted SG&A expense as a percentage of adjusted revenue.

We use the term “adjusted R&D expense” to refer to GAAP R&D expense, excluding amortization of intangible assets. We use the related term “adjusted R&D percentage” to refer to adjusted R&D expense as a percentage of adjusted revenue.

We use the term “adjusted operating income,” to refer to GAAP operating income, including revenue from contracts acquired in acquisitions that will not be fully recognized due to accounting rules, and excluding amortization of intangible assets, other purchase accounting adjustments, acquisition and divestiture-related expenses, significant litigation matters, significant environmental charges, and restructuring and contract termination charges. We use the related terms “adjusted operating profit percentage,” “adjusted operating profit margin,” or “adjusted operating margin” to refer to adjusted operating income as a percentage of adjusted revenue.

We use the term “adjusted earnings per share,” or “adjusted EPS,” to refer to GAAP earnings per share, including revenue from contracts acquired in acquisitions that will not be fully recognized due to accounting rules, and excluding discontinued operations, amortization of intangible assets, other purchase accounting adjustments, acquisition and divestiture-related expenses, significant litigation matters, significant environmental charges, disposition of businesses and assets, net, and restructuring and contract termination charges. We also exclude adjustments for mark-to-market accounting on post-retirement benefits, therefore only our projected costs have been used to calculate our non-GAAP measure. We also adjust for any tax impact related to the above items, and exclude the impact of significant tax events.

Management includes or excludes the effect of each of the items identified below in the applicable non-GAAP financial measure referenced above for the reasons set forth below with respect to that item:

  • Amortization of intangible assets— purchased intangible assets are amortized over their estimated useful lives and generally cannot be changed or influenced by management after the acquisition. Accordingly, this item is not considered by management in making operating decisions. Management does not believe such charges accurately reflect the performance of our ongoing operations for the period in which such charges are incurred.
  • Revenue from contracts acquired in acquisitions that will not be fully recognized due to accounting rules—accounting rules require us to account for the fair value of revenue from contracts assumed in connection with our acquisitions. As a result, our GAAP results reflect the fair value of those revenues, which is not the same as the revenue that otherwise would have been recorded by the acquired entity. We include such revenue in our non-GAAP measures because we believe the fair value of such revenue does not accurately reflect the performance of our ongoing operations for the period in which such revenue is recorded.
  • Other purchase accounting adjustments—accounting rules require us to adjust various balance sheet accounts, including inventory and deferred rent balances to fair value at the time of the acquisition. As a result, the expenses for these items in our GAAP results are not the same as what would have been recorded by the acquired entity. Accounting rules also require us to estimate the fair value of contingent consideration at the time of the acquisition, and any subsequent changes to the estimate or payment of the contingent consideration and purchase accounting adjustments are charged to expense or income. We exclude the impact of any changes to contingent consideration from our non-GAAP measures because we believe these expenses or benefits do not accurately reflect the performance of our ongoing operations for the period in which such expenses or benefits are recorded.
  • Acquisition and divestiture-related expenses—we incur legal, due diligence, stay bonuses, interest expense, foreign exchange gains and losses, significant acquisition integration expenses and other costs related to acquisitions and divestitures. We exclude these expenses from our non-GAAP measures because we believe they do not reflect the performance of our ongoing operations.
  • Restructuring and contract termination charges—restructuring and contract termination expenses consist of employee severance and other exit costs as well as the cost of terminating certain lease agreements or contracts. Management does not believe such costs accurately reflect the performance of our ongoing operations for the period in which such costs are reported.
  • Adjustments for mark-to-market accounting on post-retirement benefits—we exclude adjustments for mark-to-market accounting on post-retirement benefits, and therefore only our projected costs are used to calculate our non-GAAP measures. We exclude these adjustments because they do not represent what we believe our investors consider to be costs of producing our products, investments in technology and production, and costs to support our internal operating structure.
  • Significant litigation matters—we incur expenses related to significant litigation matters. Management does not believe such charges accurately reflect the performance of our ongoing operations for the periods in which such charges were incurred.
  • Significant environmental charges—we incur expenses related to significant environmental charges. Management does not believe such charges accurately reflect the performance of our ongoing operations for the periods in which such charges were incurred.
  • Disposition of businesses and assets, net—we exclude the impact of gains or losses from the disposition of businesses and assets from our adjusted earnings per share. Management does not believe such gains or losses accurately reflect the performance of our ongoing operations for the period in which such gains or losses are reported.
  • Impact of foreign currency changes on the current period—we exclude the impact of foreign currency from these measures by using the prior period’s foreign currency exchange rates for the current period because foreign currency exchange rates are subject to volatility and can obscure underlying trends.
  • Impact of significant tax events – we exclude the impact of significant tax events, such as the Tax Cuts and Jobs Act of 2017. Management does not believe the impact of significant tax events accurately reflects the performance of our ongoing operations for the periods in which the impact of such events were recorded.

The tax effect for discontinued operations is calculated based on the authoritative guidance in the Financial Accounting Standards Board’s Accounting Standards Codification 740, Income Taxes. The tax effect for amortization of intangible assets, inventory fair value adjustments related to business acquisitions, changes to the fair values assigned to contingent consideration, other costs related to business acquisitions and divestitures, significant litigation matters, significant environmental charges, adjustments for mark-to-market accounting on post-retirement benefits, disposition of businesses and assets, net, restructuring and contract termination charges, and the revenue from contracts acquired with various acquisitions is calculated based on operational results and applicable jurisdictional law, which contemplates tax rates currently in effect to determine our tax provision. The tax effect for the impact from foreign currency exchange rates on the current period is calculated based on the average rate currently in effect to determine our tax provision.

The non-GAAP financial measures described above are not meant to be considered superior to, or a substitute for, our financial statements prepared in accordance with GAAP. There are material limitations associated with non-GAAP financial measures because they exclude charges that have an effect on our reported results and, therefore, should not be relied upon as the sole financial measures by which to evaluate our financial results. Management compensates and believes that investors should compensate for these limitations by viewing the non-GAAP financial measures in conjunction with the GAAP financial measures. In addition, the non-GAAP financial measures included in this earnings announcement may be different from, and therefore may not be comparable to, similar measures used by other companies.

Each of the non-GAAP financial measures listed above is also used by our management to evaluate our operating performance, communicate our financial results to our Board of Directors, benchmark our results against our historical performance and the performance of our peers, evaluate investment opportunities including acquisitions and discontinued operations, and determine the bonus payments for senior management and employees.

Contacts

Investor Relations:
PerkinElmer, Inc.
Tommy J. Thomas, CPA (781) 663-5889
tommy.thomas@perkinelmer.com

Media Contact:
PerkinElmer, Inc.
Fara Goldberg (781) 663-5699
fara.goldberg@perkinelmer.com

Contacts

Investor Relations:
PerkinElmer, Inc.
Tommy J. Thomas, CPA (781) 663-5889
tommy.thomas@perkinelmer.com

Media Contact:
PerkinElmer, Inc.
Fara Goldberg (781) 663-5699
fara.goldberg@perkinelmer.com